IN2015DN03327A - - Google Patents

Info

Publication number
IN2015DN03327A
IN2015DN03327A IN3327DEN2015A IN2015DN03327A IN 2015DN03327 A IN2015DN03327 A IN 2015DN03327A IN 3327DEN2015 A IN3327DEN2015 A IN 3327DEN2015A IN 2015DN03327 A IN2015DN03327 A IN 2015DN03327A
Authority
IN
India
Prior art keywords
processes
preparation
pharmaceutical compositions
relates
viral infections
Prior art date
Application number
Other languages
English (en)
Inventor
Vincent Gembus
Philippe Jubault
Christophe Hoarau
Vincent Levacher
Jean-François Bonfanti
Gowan David Graig Mc
Jérôme Emile Georges Guillemont
Original Assignee
Centre Nat Rech Scient
Univ Rouen
Inst Nat Sciences Appliq
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Rouen, Inst Nat Sciences Appliq filed Critical Centre Nat Rech Scient
Publication of IN2015DN03327A publication Critical patent/IN2015DN03327A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075Two hetero atoms, in positions 3 and 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
IN3327DEN2015 2012-10-01 2013-10-01 IN2015DN03327A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306196.2A EP2712866A1 (en) 2012-10-01 2012-10-01 1,2,4-triazine derivatives for the treatment of viral infections
PCT/EP2013/070488 WO2014053516A1 (en) 2012-10-01 2013-10-01 1,2,4-triazine derivatives for the treatment of viral infections.

Publications (1)

Publication Number Publication Date
IN2015DN03327A true IN2015DN03327A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-10-09

Family

ID=46982496

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3327DEN2015 IN2015DN03327A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-10-01 2013-10-01

Country Status (21)

Country Link
US (1) US9416114B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP2712866A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6298998B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102138393B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104812747B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013326579B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112015007310B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2886630C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2015000787A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA026236B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2616496T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL237871A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2015DN03327A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX348229B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY182558A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ706354A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12015500724B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201502522WA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA114644C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014053516A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201502240B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62254B1 (sr) 2011-04-08 2021-09-30 Janssen Sciences Ireland Unlimited Co Derivati pirimidina za tretman virusnih infekcija
HRP20181497T1 (hr) 2011-11-09 2018-11-30 Janssen Sciences Ireland Uc Derivati purina za liječenje virusnih infekcija
EP2872515B1 (en) 2012-07-13 2016-06-08 Janssen Sciences Ireland UC Macrocyclic purines for the treatment of viral infections
MX386924B (es) 2012-10-10 2025-03-19 Janssen Sciences Ireland Uc Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades.
DK2925729T3 (en) 2012-11-16 2018-01-22 Janssen Sciences Ireland Uc HETEROCYCLIC SUBSTITUTED 2-AMINOQUINAZOLINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
JP6404835B2 (ja) 2013-02-21 2018-10-17 ヤンセン・サイエンシズ・アイルランド・ユーシー ウイルス感染の治療のための2−アミノピリミジン誘導体
EA202090547A3 (ru) 2013-03-29 2020-12-30 Янссен Сайенсиз Айрлэнд Юси Макроциклические деаза-оксипурины для лечения вирусных инфекций
SG11201509520QA (en) 2013-05-24 2015-12-30 Janssen Sciences Ireland Uc Pyridone derivatives for the treatment of viral infections and further diseases
AU2014301089B2 (en) 2013-06-27 2018-10-04 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
MY179503A (en) 2013-07-30 2020-11-09 Janssen Sciences Ireland Uc Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
CA3027471A1 (en) 2016-07-01 2018-01-04 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines for the treatment of viral infections
SG10202010317VA (en) * 2016-09-29 2020-11-27 Janssen Sciences Ireland Unlimited Co Pyrimidine prodrugs for the treatment of viral infections and further diseases
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 2,4-二胺基喹唑啉衍生物及其醫學用途
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Toll-like受容体7または8アゴニストとコレステロールの結合体およびその用途
CN115666637A (zh) 2020-03-02 2023-01-31 蛋白科技先锋 基于病原体细胞壁骨架的模拟活病原体的纳米粒子及其制备方法
US20230355750A1 (en) 2020-08-04 2023-11-09 Progeneer Inc. Kinetically acting adjuvant ensemble
EP4194010A4 (en) 2020-08-04 2025-03-26 Progeneer Inc. Conjugate of a functional drug and a toll-like receptor 7 or 8 agonist with a temporarily inactivated drug site, and use thereof
EP4194006A4 (en) 2020-08-04 2024-12-04 Progeneer Inc. mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL
WO2024151953A1 (en) * 2023-01-15 2024-07-18 Viradem Inc. Compounds and methods for treating diseases caused by sars-cov-2 and other coronaviruses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485531A1 (fr) * 1980-06-25 1981-12-31 Fabre Sa Pierre Nouveaux n-oxydes de diaryl-5,6 as triazines 1-2-4, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
ATE283855T1 (de) 1996-07-03 2004-12-15 Sumitomo Pharma Neue purinderivate
WO1999028321A1 (fr) 1997-11-28 1999-06-10 Sumitomo Pharmaceuticals Company, Limited Nouveaux composes heterocycliques
AU2005271161B2 (en) * 2004-08-10 2011-05-12 Janssen Pharmaceutica N.V. HIV inhibiting 1,2,4-triazin-6-one derivatives
EA200702235A1 (ru) 2005-05-04 2008-04-28 Пфайзер Лимитед Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
CN101296907B (zh) * 2005-09-01 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类
RU2352565C1 (ru) * 2007-10-08 2009-04-20 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" 3-амино-6-ароилметил-5-гидрокси-1,2,4-триазины и способ их получения
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
WO2012067269A1 (en) * 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease

Also Published As

Publication number Publication date
JP2015535839A (ja) 2015-12-17
CL2015000787A1 (es) 2015-10-02
AU2013326579A1 (en) 2015-04-09
PH12015500724A1 (en) 2015-06-01
MX2015004160A (es) 2016-02-05
KR102138393B1 (ko) 2020-08-14
MY182558A (en) 2021-01-25
BR112015007310A2 (pt) 2017-08-08
CA2886630C (en) 2021-01-26
US20150336907A1 (en) 2015-11-26
PH12015500724B1 (en) 2015-06-01
SG11201502522WA (en) 2015-05-28
EP2903976A1 (en) 2015-08-12
NZ706354A (en) 2018-08-31
HK1208223A1 (en) 2016-02-26
EA201500383A1 (ru) 2015-07-30
BR112015007310B1 (pt) 2022-07-19
CA2886630A1 (en) 2014-04-10
CN104812747A (zh) 2015-07-29
EA026236B1 (ru) 2017-03-31
EP2712866A1 (en) 2014-04-02
CN104812747B (zh) 2017-03-08
MX348229B (es) 2017-05-31
UA114644C2 (uk) 2017-07-10
WO2014053516A1 (en) 2014-04-10
EP2903976B1 (en) 2016-12-07
US9416114B2 (en) 2016-08-16
ZA201502240B (en) 2016-05-25
JP6298998B2 (ja) 2018-03-28
ES2616496T3 (es) 2017-06-13
IL237871A (en) 2017-04-30
KR20150084791A (ko) 2015-07-22
AU2013326579B2 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
IN2015DN03327A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
PH12015500983A1 (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
PH12015501648B1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
PH12015502261A1 (en) Macrocyclic deaza-purinones for the treatment of viral infections
PH12015502797A1 (en) THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12014501045B1 (en) Purine derivatives for the treatment of viral infections
PH12015502564B1 (en) Pyridone derivatives for the treatment of viral infections and further diseases